EMORY UNIVERSITY Sample Clauses

EMORY UNIVERSITY. By: <<s:sig2 >> (Signature)
AutoNDA by SimpleDocs
EMORY UNIVERSITY. “A Climate Action Plan for Emory University.” Emory University, December 2011. xxxx://xxxxxxxxxxxxxx.xxxxx.xxx/uploads/articles/2013/07/2013073112062066/Emory_Uni versity_Climate_Action_Plan_7.19.13.pdf. ———. “Emory Greenhouse Gas Emissions Inventory FY 2014 Update.” Emory University, July 2017. xxxxx://xxxxxxxxxxxxxx.xxxxx.xxx/wp- content/uploads/2018/02/2014_GHG_Summary_Analysis_FINAL_8.15.17.pdf ———. “Facts and Figures About Emory | Emory University | Emory University | Atlanta, GA.” Accessed October 17, 2018. xxxx://xxx.xxxxx.xxx/home/about/factsfigures/index.html. Emory University Office of the Xxxxxxx. “One Emory: Engaged for Impact | Xxxxxxx | Xxxxx University.” Accessed January 24, 2019. xxxx://xxxxxxx.xxxxx.xxx/production-test- 2018/work/strategic-framework.html. Xxxxxx, Xxxxxx, Xxxxx X XxXxxxx, XxXxxxx Xxxxx, and Xxxxx X Xxxxxx. “Assessing the Emission Benefits of Renewable Energy and Energy Efficiency Using EPA’s AVoided Emissions and GeneRation Tool (AVERT),” n.d., 21. Xxxxxxx, Xxxxxxxx, and Xxxx Xxxxxxxx. “When Should the Ask Be a Nudge? The Effect of Default Amounts on Charitable Donations.” Journal of Marketing Research (JMR) 53, no. 5 (October 2016): 829–46. xxxxx://xxx.xxx/10.1509/jmr.15.0001.
EMORY UNIVERSITY. By /s/ Xxxx X. Xxxxxx ------------------ January 31, 1996 ---------------- Date THE ROCKEFELLER UNIVERSITY will promptly reimburse EMORY UNIVERSITY its share of the patent expenses paid to THE ROCKEFELLER UNIVERSITY pursuant to Paragraph 4.1 hereof. Additionally, and in consideration of EMORY UNIVERSITY'S joining in the license grant as above provided, THE ROCKEFELLER UNIVERSITY agrees to pay to EMORY UNIVERSITY *****/1/ of the net monies received by THE ROCKEFELLER UNIVERSITY pursuant to Paragraph 3 thereof. THE ROCKEFELLER UNIVERSITY By /s/ Xxxxxxxxx X. Xxxx ------------------------ Executive Vice President

Related to EMORY UNIVERSITY

  • University Any notice may be served upon the University by delivering it, in writing, to the University at the address set forth on the last page of this Agreement, by depositing it in a United States Postal Service deposit box with the postage fully prepaid and with the notice addressed to the University at the aforementioned address, or by sending a facsimile of it to the University facsimile number set forth on the last page of this Agreement.

  • Middle School At the request of the Superintendent, a middle school teacher may volunteer on a semester basis to teach all the student contact time and be paid one-sixth (1/6) of his/her salary for the semester. This section shall not be used to circumvent the hiring of additional full time teachers.

  • Licensor any Person from whom a Grantor obtains the right to use any Intellectual Property. Lien: any Person’s interest in Property securing an obligation owed to, or a claim by, such Person, whether such interest is based on common law, statute or contract, including liens, security interests, pledges, hypothecations, statutory trusts, reservations, exceptions, encroachments, easements, rights-of-way, covenants, conditions, restrictions, leases, and other title exceptions and encumbrances affecting Property. Lien Waiver: an agreement, in form and substance satisfactory to Collateral Agent, by which (a) for any material Collateral located on leased premises, the lessor waives or subordinates any Lien it may have on the Collateral, and agrees to permit Collateral Agent to enter upon the premises and remove the Collateral or to use the premises to store or dispose of the Collateral; (b) for any Collateral held by a warehouseman, processor, shipper, customs broker or freight forwarder, such Person waives or subordinates any Lien it may have on the Collateral, agrees to hold any Documents in its possession relating to the Collateral as agent for Collateral Agent, and agrees to deliver the Collateral to Collateral Agent upon request; (c) for any Collateral held by a repairman, mechanic or bailee, such Person acknowledges Collateral Agent’s Lien, waives or subordinates any Lien it may have on the Collateral, and agrees to deliver the Collateral to Collateral Agent upon request; and (d) for any Collateral subject to a Licensor’s Intellectual Property rights, the Licensor grants to Collateral Agent the right, vis-à-vis such Licensor, to enforce Collateral Agent’s Liens with respect to the Collateral, including the right to dispose of it with the benefit of the Intellectual Property, whether or not a default exists under any applicable License.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

  • Technology Research Analyst Job# 1810 General Characteristics Maintains a strong understanding of the enterprise’s IT systems and architectures. Assists in the analysis of the requirements for the enterprise and applying emerging technologies to support long-term business objectives. Responsible for researching, collecting, and disseminating information on emerging technologies and key learnings throughout the enterprise. Researches and recommends changes to foundation architecture. Supports research projects to identify and evaluate emerging technologies. Interfaces with users and staff to evaluate possible implementation of the new technology in the enterprise, consistent with the goal of improving existing systems and technologies and in meeting the needs of the business. Analyzes and researches process of deployment and assists in this process.

Time is Money Join Law Insider Premium to draft better contracts faster.